

Attorney Docket No.: 10096.200-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Callisen, Thomas Honger Confirmation No: 9485

**FAX RECEIVED**Serial No.: 10/005,321 Group Art Unit: 1615

MAR 21 2003

Filed: December 3, 2001 Examiner: R. Bennett

**GROUP 1600**

For: Encapsulation Of Compounds In Vesicles

## CERTIFICATE OF FACSIMILE TRANSMISSION

**OFFICIAL**Commissioner for Patents  
Washington, DC 20231


Sir:

I hereby certify that the attached correspondence comprising:

## 1. Response to Restriction Requirement

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner R. Bennett, fax number (703) 305-3592.

Respectfully submitted,

  
\_\_\_\_\_  
Lourdes Ayala  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

Date: March 20, 2003

#5  
MP  
O 3/25/03  
PATENT

Attorney Docket No.: 10096.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Callisen, Thomas Honger Confirmation No: 9485

Serial No.: 10/005,321 Group Art Unit: 1615

Filed: December 3, 2001 Examiner: R. Bennett

For: Encapsulation Of Compounds In Vesicles

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:

This paper is filed in response to the Office Action mailed February 21, 2003 that made restriction and election of species requirements. Applicants were requested to elect one of two designated groups.

In response to these requirements, Applicants hereby elect with traverse the invention of Group II, i.e., claims 6-9, and the method of claim 5 as the species. Claim 5 reads on the elected species. Applicants hereby reserve the right to file continuing applications directed to the nonelected subject matter.

The basis for traverse is that there would not be a serious burden on the examiner if an election of species was not required.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: March 20, 2003

  
Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097